Company: SMNR
Filing Date: 2025-07-23
Form Type: S-4/A
Source: 0001193125-25-163401
Chunk: 408

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-07-23
Form: S-4/A
Chunk 408
---
     | provide that the Denali Board be divided into three classes with only one class of directors being elected each year and each class serving three year terms; |

| • |     | require the removal of any director be only for cause and by the affirmative vote of at least 66 2/3% of the voting power of all then-outstanding shares of stock of New Semnur entitled to vote thereon, voting together as a single class, from and after the Scilex Trigger Event (and prior to such event, by the affirmative vote of the holders of a majority of voting power of the then-outstanding shares of stock of New Semnur entitled to vote generally in the election of such directors); |

| • |     | provide that from and after the Scilex Trigger Event, the alteration, amendment or repeal of certain provisions of the Proposed Charter will require the affirmative vote of the holders of at least 66 2/3% of the voting power of the then-outstanding shares of stock entitled to vote thereon, voting together as a single class; |

| • |     | provide that from and after the Scilex Trigger Event, the alteration, amendment or repeal of the Proposed Bylaws will require the affirmative vote of the holders of at least 66 2/3% of the voting power of the then-outstanding shares of stock entitled to vote thereon, voting together as a single class; |

| • |     | provide that from and after the Scilex Trigger Event, stockholders will not be permitted to act by written consent in lieu of holding a meeting of stockholders; and |

| • |     | provide for certain additional changes, including, among other things, removing certain provisions related to Denali’s status as a blank check company that will no longer apply upon consummation of the Business Combination. |

In addition, the Denali Board will take such actions as are necessary to change the post-Business Combination company’s corporate name from “Denali Capital Acquisition Corp.” to “Semnur Pharmaceuticals, Inc.” and to remove provisions relating to the incorporator and initial board of directors following the Domestication and prior to the Effective Time. Reasons for the Approval of the Charter Approval Proposal In the judgment of the Denali Board, the Proposed Charter is necessary to adequately address the needs of the post-Business Combination company. In particular:

| • |     | The Proposed Charter provides for authorized capital stock of 785,000,000 shares, consisting of 740,000